

# Dispelling Myths about Nicotine Replacement Therapy

<http://www.smokefree.gov>

**Myth:** *Nicotine Replacement Therapy (NRT) does not work.*

**Truth:** NRT does work. NRT can double a smoker's chances of quitting smoking.<sup>1,2,8</sup> The likelihood of staying quit for more than six months is increased when a smoker uses NRT according to the directions.<sup>8-9</sup>

**Myth:** *The nicotine in cigarettes is the same as the nicotine found in Nicotine Replacement Therapy (NRT) products, so I'm just trading one addiction for another.*

**Truth:** No, the products are different and the likelihood of long-term addiction to NRT is very low.<sup>1,2</sup> The nicotine found in NRT is regulated by the Federal Drug Administration (FDA).<sup>3</sup> The amount of nicotine in NRT is less than in cigarettes and it is delivered more slowly.<sup>4-6</sup> NRT products have a much lower risk of addiction than cigarettes.<sup>2, 7</sup>

**Myth:** *If I use NRT, I will experience no withdrawal symptoms or cravings from quitting smoking.*

**Truth:** NRT does reduce withdrawal symptoms associated with cigarette smoking. However, it may not completely eliminate them. The symptoms most helped by NRT include: irritability, frustration, anger, craving, hunger, anxiety, difficulty concentrating, restlessness, and insomnia.<sup>10</sup> NRT achieves the best results when combined with a personal quit plan.

**Myth:** *NRT causes disease.*

**Truth:** The effect of NRT on the body is not fully known, but NRT products are safer than cigarettes.<sup>2,7</sup> The negative health effects of cigarettes are proven.<sup>8,11,12</sup> Of the 4,000 chemicals found in tobacco smoke, over 60 are known to cause cancer.<sup>13</sup> By using NRT to quit smoking you reduce your exposure to many chemicals found in tobacco smoke.

**Myth:** *If I use one NRT product, I cannot use others.*

**Truth:** No, NRT products can be used alone or in combination.<sup>1,10,14</sup> Talk to your doctor before doing so.

**Myth:** *NRT is too expensive.*

**Truth:** Over time the cost of NRT is less expensive than the cost of cigarettes. NRT is generally used for a limited time, whereas cigarettes are typically consumed many years.<sup>6</sup> Compare the price of the NRT products to the average price of \$3.51 for a package of 20 cigarettes in South Carolina (lowest in the United States) and the \$5.96 for a package of 20 cigarettes in Alaska.<sup>9</sup>

NRT Product	Average Daily Cost <sup>10</sup>
Nicotine Nasal Spray	\$3.40
Nicotine Patches	\$3.91
Nicotine Lozenges	\$4.98
Nicotine Gum	\$5.81
Nicotine Inhaler	\$6.07

**Myth:** *Only healthy people can use NRT.*

**Truth:** Under the direction of your doctor most people can use NRT. Generally, NRT can be safely used by people with diabetes or high blood pressure and does not increase the risk of heart attacks.<sup>6,15-27</sup> Talk to your doctor to determine if NRT is the right choice for your quit plan.

## References

1. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. 2004. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*:CD000146
2. Luty J. 2002. Nicotine addiction and smoking cessation treatments. *Advances in Psychiatric Treatment* 8:42-48.
3. Gray N, Henningfield JE, Benowitz NL, Connolly GN, Dresler C, Fagerstrom K, Jarvis MJ, Boyle P. Toward a comprehensive long term nicotine policy. *Tob Control*. 2005 Jun;14(3):161-5.
4. Shiffman S, Dresler CM, Hajek P, Gilbert SJA, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med*. 2002;162:1267-1276.
5. Benowitz NL, ed. *Nicotine Safety and Toxicity*. Oxford University Press; 1998:224.
6. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. *Nicotine Tob Res*. 2003;5(5):635-44.
7. Stratton K, Shetty P, Wallace R, Bondurant S. (Eds.) (2001). *Clearing the smoke: assessing the science base for tobacco harm*. Institute of Medicine. Washington DC: National Academy Press.
8. Smith CJ, Livingston SD, Doolittle DJ. An international literature survey of "IARC Group I carcinogens" reported in mainstream cigarette smoke. *Food Chem Toxicol* 1997; 35: 1107-1130.
9. Orzechowski B, Walker R. The Tax Burden on Tobacco, Volume 40. 2005.
10. Schroeder SA. What to do with a patient who smokes. *JAMA* 2005;294(4):482-7.
11. Hoffman and Hoffman. The changing cigarette, 1950-1995. *J Toxicol Environ Health* 1997;50:307-364.
12. Centers for Disease Control and Prevention. *Tobacco Use in the United States*. Retrieved December 15, 2006, from: [http://www.cdc.gov/tobacco/overview/tobus\\_us.htm](http://www.cdc.gov/tobacco/overview/tobus_us.htm).
13. Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion. Toxic chemicals in tobacco products. Available at: [www.cdc.gov/tobacco/research\\_data/product/objective21-20.htm](http://www.cdc.gov/tobacco/research_data/product/objective21-20.htm). Accessed January 4, 2007.
14. Bars MP, Banauch GI, Appel D, Andreachi M, Mouren P, Kelly KJ, et al. "Tobacco Free With FDNY": the New York City Fire Department World Trade Center Tobacco Cessation Study. *Chest* 2006;129(4):979-87.
15. Eliasson B, Taskinen MR, Smith U. Long-term of nicotine gum is associated with hyperinsulinemia and insulin resistance. *Circulation*. 1996;94:878-881.
16. Epifano L, Di Vincenzo A, Fanelli C, et al. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus. *Eur J Clin Pharmacol*. 1992;43:-237-263.
17. Assali AR, Beigei Y, Schreiberman R, Shafer Z, Fainaru M. Weight gain and insulin resistance during nicotine replacement therapy. *Clin Cardiol*. 1999;22:357-360.
18. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. *Arch Intern Med*. 1994;154:989-995.
19. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. *N Engl J Med*. 1996;335:1792-1798.
20. Pardell H, Tresserras R, Salto E, Armario P, Hernandez R. Management of the hypertensive patient who smokes. *Drugs*. 1998;56:177-187.
21. Tanos-Santos Je, Toledo JCY, Cittadino M, et al. Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers. *Am J Hypertens*. 2001;14:610-614.
22. Kimmel SE, Berlin JA, Miles C, Jaskowiak J, Carson JL, Strom BL. Risk of acute first myocardial infarction and use of nicotine patches in a general population. *J Am Coll Cardiol*. 2001;37:1297-1302.
23. Greenland S, Satterfield MN, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. *Drug Safety*. 1998;18:297-308.
24. Basler H-D, Brinkmeier U, Buser K, Gluth G. Nicotine gum assisted group therapy in smokers with an increased risk of coronary disease—evaluation in a primary care setting format. *Health Education Research*. 1992;7:87-95.
25. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. *Chest*. 1996. 109:438-445.
26. Keeley EC, Pirwitz MJ, Landau C, et al. Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions. *Am J Med*. 1996;171:357-363.
27. Ludviksdottir D, Blondal T, Franzon M, Gudmundsson TV, Sawe U. Effects of nicotine nasal spray on atherogenic and thrombogenic factors during smoking. *J Intern Med*. 1999;246:61-66.